Scarica l'app Stockscreener
192.50
7.46%
13.36
Pre-mercato:
192.52
0.02
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DHR Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$179.14
Aprire:
$185.12
Volume 24 ore:
11.52M
Relative Volume:
2.22
Capitalizzazione di mercato:
$135.32B
Reddito:
$24.78B
Utile/perdita netta:
$3.68B
Rapporto P/E:
37.20
EPS:
5.1743
Flusso di cassa netto:
$5.29B
1 W Prestazione:
-6.10%
1M Prestazione:
+7.56%
6M Prestazione:
-18.09%
1 anno Prestazione:
-2.72%
Intervallo 1D:
$183.87
$192.89
Intervallo di 1 settimana:
$165.75
$206.59
Portata 52W:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Nome
Danaher Corp
Settore
Industria
Telefono
(202) 828-0850
Indirizzo
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-03-14 | Aggiornamento | Stifel | Hold → Buy |
| 2025-02-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-19 | Iniziato | Guggenheim | Buy |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-31 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Iniziato | HSBC Securities | Hold |
| 2023-12-13 | Ripresa | Wolfe Research | Peer Perform |
| 2023-12-07 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-01 | Iniziato | SVB Securities | Outperform |
| 2023-04-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-10-24 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-17 | Ripresa | Bernstein | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-06-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Iniziato | Bernstein | Outperform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-10 | Reiterato | BofA Securities | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Reiterato | Goldman | Buy |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-04-07 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-03 | Ripresa | Barclays | Overweight |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Reiterato | Needham | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Ripresa | Stifel | Hold |
| 2019-10-28 | Reiterato | Needham | Buy |
| 2019-10-14 | Ripresa | Credit Suisse | Outperform |
| 2019-07-19 | Reiterato | Needham | Buy |
| 2019-06-11 | Iniziato | Piper Jaffray | Neutral |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-28 | Reiterato | Needham | Buy |
| 2019-02-25 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-04-20 | Reiterato | Stifel | Buy |
Mostra tutto
Danaher Corp Borsa (DHR) Ultime notizie
Danaher Corp (DHR) Stock Up 7.5% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send? - TradingKey
Beckman Coulter Diagnostics Launches Fully Automated Urinalysis System to Meet Rising Testing Volumes - Financial Times
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI - Bitget
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com South Africa
Danaher stock trades steady as investors weigh life sciences growth and recent margin trends - Ad-hoc-news.de
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com South Africa
Stifel cuts Danaher stock price target on bioprocess weakness - Investing.com UK
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
Don't quit on Danaher stock after horrific earnings reaction - MSN
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Canada
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
Leerink Partners Adjusts Price Target on Danaher to $240 From $270, Maintains Outperform Rating - Moomoo
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Danaher to $210 From $230, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Reports Q3 Revenue Growth of 2%-3% Year-over-Year - GuruFocus
Don’t Quit on Danaher Stock After Horrific Earnings Reaction - Barron's
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred - TradingView
Geopolitical Conflicts and Energy Shocks Cloud Danaher’s 2026 Financial Outlook - TipRanks
DHR SWOT Analysis: Strong Financials Amidst Competitive Challenges Revealed in 10-Q Filing - GuruFocus
Danaher (DHR) Q2 2026 Earnings Call Transcript - The Motley Fool
Danaher (DHR) Reports Strong Q2 Earnings, Stock Drops Due to Ord - GuruFocus
Danaher Earnings Call Signals Growing Core Momentum - TipRanks
Danaher (DHR) Reports Strong Q2 2026 Results and Raises EPS Guid - GuruFocus
Danaher Corporation’s Stock Price Plummets to $179.01, Registering a Sharp 10.99% Drop - Smartkarma
Is Danaher Corp (DHR) a Bargain After 11.0% Drop? GF Value Says Undervalued - GuruFocus
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet - Investor's Business Daily
Danaher (DHR) Reports Strong Q2 Earnings, Raises Full-Year Guida - GuruFocus
Danaher Posts Strong Q2 Results Driven By Life Sciences And Masimo Acquisition - insights.citeline.com
Danaher Corporation Provides Revenue Guidance for the Third Quarter 2026 - marketscreener.com
Why Danaher (DHR) Shares Are Falling Today - Yahoo Finance
Danaher (NYSE:DHR) in Focus on A Heavy Earnings Day For Healthcare - Kalkine Media
Danaher Corp Azioni (DHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
8.71%
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):